Related Experiment Video

Updated: Jun 8, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

Arterial hypertension in children: few clinical trials

    Prescrire International
    |October 14, 2010
    PubMed

    Insights

    Pediatric arterial hypertension, defined statistically, is uncommon and often linked to underlying conditions. Lifestyle changes are primary, with medication reserved for severe cases, favoring specific diuretics and beta-blockers.

    Area of Science:

    • Pediatrics
    • Cardiology
    • Nephrology

    Background:

    • Arterial hypertension in children is statistically defined by age, gender, and height.
    • Pediatric hypertension is rare, with limited data on its clinical impact.
    • Underlying causes, such as obesity and organ-specific disorders, are more common in children than adults.

    Purpose of the Study:

    • To review the definition, causes, and management of arterial hypertension in pediatric populations.
    • To highlight the importance of identifying secondary causes of hypertension in children.
    • To provide guidance on the appropriate use of pharmacotherapy when necessary.

    Main Methods:

    • Statistical definition of hypertension in children.
    • Review of etiological factors associated with pediatric hypertension.
    • Analysis of current management strategies, including lifestyle modifications and pharmacotherapy.

    Main Results:

    • Hypertension in children requires a statistical definition considering demographic factors.
    • Overweight, renal, cardiac, and endocrine disorders are frequent underlying causes.
    • The efficacy of antihypertensive drugs on morbidity and mortality is not well-established in children.

    Conclusions:

    • Management prioritizes lifestyle modifications for hypertensive children.
    • Antihypertensive drug therapy should be used cautiously when unavoidable.
    • Specific diuretics and beta-blockers are recommended if pharmacotherapy is initiated.

    Related Concept Videos

    Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

    Hypertension III: Clinical Manifestations and Diagnostic Studies

    Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
    Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

    Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

    Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
    Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

    Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

    Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
    ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
    Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

    Pharmacokinetics in Pediatric Patients: Drug Distribution

    Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
    Hypertension I: Introduction01:28

    Hypertension I: Introduction

    Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...
    Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

    Pharmacokinetics in Pediatric Patients: Drug Metabolism

    In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...